Moleculin Biotech, Inc.
MBRX
$2.41
-$0.06-2.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.37% | 12.11% | |||
| Depreciation & Amortization | -11.11% | -57.14% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.53% | 27.55% | |||
| Operating Income | -4.53% | -27.55% | |||
| Income Before Tax | -182.59% | 161.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -182.59% | 161.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -182.59% | 161.23% | |||
| EBIT | -4.53% | -27.55% | |||
| EBITDA | -4.55% | -27.87% | |||
| EPS Basic | -151.34% | 140.53% | |||
| Normalized Basic EPS | -144.84% | 140.81% | |||
| EPS Diluted | -151.34% | 140.53% | |||
| Normalized Diluted EPS | -144.84% | 140.81% | |||
| Average Basic Shares Outstanding | 84.21% | 50.05% | |||
| Average Diluted Shares Outstanding | 84.21% | 50.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||